Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month.Weight loss drugs like Zepbound and Novo Nordisk's Ozempic aren't covered under Medicare,
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to secure CMS coverage for obesity drugs.
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over
CMS confirms to CNBC Medicare plans can now cover Zepbound for sleep apnea
The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli Lilly's drug Zepbound,
Rolling Out3h
Snoring and choking may signal sleep apnea or paralysis
A loved one waking you with loud snoring, followed by gasping and choking sounds, might signal more than minor sleep ...
Apple Watch's Sleep Apnea Feature Continues to Roll Out Around World
Apple this month received approval to launch the Apple Watch's sleep apnea notifications feature in Malaysia, as noted by ...
How eating more cheese may be the secret to getting better sleep
There’s gouda news for cheese lovers. A recent study found cheese eaters are less likely to have sleep apnea than their dairy ...
Rolling Out1d
How a sleep mask for apnea reduces high blood pressure risk
Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...
New imaging technique could transform obstructive sleep apnea diagnosis
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...
Future Market Insights3d
Sleep Apnea Diagnostic Systems Industry to Nearly Double, Reaching USD 9.27 Billion by 2033 at a 6.8% of CAGR
The sleep apnea diagnostic systems market is expected to grow from US$ 4.81 billion in 2023 to US$ 9.27 billion by 2033, at a ...
What’s the best diet for healthy sleep? A nutritional epidemiologist explains what food choices will help you get more restful z’s
You probably already know that how you eat before bed affects your sleep. Maybe you’ve found yourself still lying awake at 2 ...
Community Impact Newspaper4d
Dr. Jennifer Buchanan finds relief from sleep apnea with Spark Clear Aligners
Buchanan Orthodontics offers orthodontic treatment for patients of all ages with Damon Braces, Spark Clear Aligners and ...